Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aequus PharmaceuticalsAQSZF 3-Year RORE % is -34.88 as of Sep. 2025. The stock has 6 warning signs investors should review. Among 941 Drug Manufacturers companies, Aequus Pharmaceuticals ranks worse than 75.45% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Aequus Pharmaceuticals's 3-Year RORE % for the quarter that ended in Sep. 2025 was -34.88%.
The industry rank for Aequus Pharmaceuticals's 3-Year RORE % or its related term are showing as below:
AQSZF's 3-Year RORE % is ranked worse than 75.45% of 941
companies
in the Drug Manufacturers industry
Industry Median: 3.06
vs AQSZF: -34.88
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Aequus Pharmaceuticals 3-Year RORE % Related Terms
Aequus Pharmaceuticals 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AQSZF vs GRPS, GCAN, STEK: 3-Year RORE % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aequus Pharmaceuticals's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aequus Pharmaceuticals 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aequus Pharmaceuticals's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Aequus Pharmaceuticals's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2025 and 3-year before.
Aequus Pharmaceuticals (AQSZF) has a 3-Year RORE % of -34.88 as of Sep. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Aequus Pharmaceuticals and its competitors. According to the industry distribution chart, Aequus Pharmaceuticals ranks #710 out of 941 companies in the Drug Manufacturers industry, placing it in the top 75.5%.
Is Aequus Pharmaceuticals' 3-Year RORE % too high?
Aequus Pharmaceuticals' current 3-Year RORE % is -34.88. Based on the distribution chart, Aequus Pharmaceuticals ranks #710 out of 941 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Aequus Pharmaceuticals' 3-Year RORE % compare to GRPS and GCAN?
According to the Drug Manufacturers industry distribution chart, Aequus Pharmaceuticals ranks #710 out of 941 companies for 3-Year RORE %. This places Aequus Pharmaceuticals in the lower half of its industry. The industry median 3-Year RORE % is 3.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.06, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Aequus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aequus Pharmaceuticals's current 3-Year RORE % is -34.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aequus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aequus Pharmaceuticals (AQSZF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 88% below its estimated fair value. The current 3-Year RORE % is -34.88. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Aequus Pharmaceuticals (AQSZF), the current 3-Year RORE % is -34.88 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products namely Tacrolimus IR and Vistitan.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AQSZF has been successfully added to your 
